Choriocarcinoma

Summary

Choriocarcinoma (MONDO:0005207) is a disease (an umbrella term covering 8 Mondo subtypes) and 10 clinical trials. Top therapeutic interventions include dactinomycin, etoposide phosphate, and ifosfamide. A subtype of trophoblastic neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 8 Mondo subtypes
• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	choriocarcinoma
Mondo ID	MONDO:0005207
EFO	EFO:0002893
MeSH	D002822
DOID	DOID:3594
NCIT	C2948
SNOMED CT	188188009
UMLS	C0008497
MedGen	40278
GARD	0006059
Is cancer (heuristic)	no

Also known as: chorioblastoma · choriocarcinoma · choriocarcinoma (disease) · choriocarcinoma, malignant · chorioepithelioma · chorion carcinoma · chorionic carcinoma

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of trophoblastic neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › trophoblastic neoplasm › choriocarcinoma

Related subtypes (3): testicular trophoblastic tumor, hydatidiform mole, gestational trophoblastic neoplasm

Subtypes (8): pulmonary artery choriocarcinoma, choriocarcinoma of ovary, choriocarcinoma of testis, gastric choriocarcinoma, non-gestational choriocarcinoma, choriocarcinoma of the central nervous system, gestational choriocarcinoma, placental site trophoblastic tumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Dactinomycin	Phase 3 (in late-stage trials)
Methotrexate	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Bevacizumab, Carotuximab.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	4
Not specified	4
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02375204	PHASE3	ACTIVE_NOT_RECRUITING	Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
NCT01535053	PHASE3	COMPLETED	Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
NCT04684368	PHASE2	RECRUITING	A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
NCT00190918	PHASE2	COMPLETED	A Trial for Patients With Gestational Trophoblastic Disease
NCT02396511	PHASE2	COMPLETED	TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma
NCT02664961	PHASE2	TERMINATED	Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
NCT04562558	Not specified	ACTIVE_NOT_RECRUITING	Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia
NCT05564026	Not specified	RECRUITING	Molecular Epidemiology of Pediatric Germ Cell Tumors
NCT00294177	Not specified	UNKNOWN	Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Choriocarcinoma
NCT01267851	Not specified	UNKNOWN	Clinical Database and Biobank of Patients With Gynecologic Neoplasms

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DACTINOMYCIN	4	2
ETOPOSIDE PHOSPHATE	4	1
IFOSFAMIDE	4	1
LEUCOVORIN	4	1
CAROTUXIMAB	3	2
CHEMBL4748391	0	2